Rheumnow Podcast
ACR24 - IL-17
Nov 24, 2024
In this engaging discussion, Philip Meese, a seasoned rheumatologist, delves into the latest advancements in IL-17 treatments for psoriatic arthritis and axial spondyloarthritis. He shares intriguing real-world data on the efficacy and safety of Bimekizumab, highlighting significant improvements in pain and fatigue. The conversation also explores treatment strategies comparing TNF and IL-17 inhibitors, revealing insights from a large patient study. Additionally, Meese discusses the long-term safety profile of Bimekizumab and other emerging therapies, emphasizing personalized patient care.
32:44
Episode guests
AI Summary
AI Chapters
Episode notes
Podcast summary created with Snipd AI
Quick takeaways
- The ACR Convergence 2024 emphasizes patient engagement through morning plenary sessions and live streaming of daily recaps for enhanced participation.
- Research highlights IL-17 inhibitors’ significant role in improving pain and fatigue, reinforcing the importance of patient-reported outcomes in treatment efficacy.
Deep dives
Key Innovations at ACR Convergence 2024
The ACR Convergence 2024 introduces several innovations aimed at enhancing attendance and participation in the meeting. One notable change is the scheduling of plenary sessions in the morning, which allows attendees to engage more effectively with the day's discussions. Additionally, there will be live streaming of daily recaps at 6 p.m. Eastern time, providing a summary of the day's highlights and notable findings for those unable to attend. Participants are encouraged to connect with experts through various platforms, including social media and the RoomNow website, to stay updated on important advancements and insights shared during the conference.
Remember Everything You Learn from Podcasts
Save insights instantly, chat with episodes, and build lasting knowledge - all powered by AI.
